Drugs / 99mTc-QULIC-5-P1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06419348 | May 2024 → Dec 2025 overdue | prostate cancer, sperm protamine P4 | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-QULIC-5-P1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06419348 ↗ |
| Modality | Diagnostic / imaging agent | “99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA” NCT06419348 ↗ |
| Route | Intravenous | “Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.” NCT06419348 ↗ |